Skip to content
Screener

Vaxcyte, Inc. PCVX Price / book

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Moderna logo
ModernaMRNA
4.1×+3.0×
Novavax logo
NovavaxNVAX
27.9×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
5.9×+0.6×
Regenxbio logo
RegenxbioRGNX
8.6×+6.6×

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Calculated from Vaxcyte, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026. Open the filing →

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017

FAQ

What is Vaxcyte, Inc.'s price / book?
Vaxcyte, Inc. (PCVX) reported price / book of 2.8× in Q1 2026.
How has Vaxcyte, Inc.'s price / book changed year-over-year?
Vaxcyte, Inc.'s price / book increased by 83.7% year-over-year, from 1.5× to 2.8×.
What is the long-term trend for Vaxcyte, Inc.'s price / book?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s price / book has grown at a -10.6% compound annual growth rate (CAGR), from 3.9× to 2.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Vaxcyte, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude